Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Childbirth Research Associates, North Hollywood, California.
J Surg Res. 2019 Jan;233:304-309. doi: 10.1016/j.jss.2018.08.022. Epub 2018 Sep 5.
Congenital pleural effusion is a rare condition with an incidence of approximately one per 15,000 pregnancies. The development of secondary hydrops is a poor prognostic indicator and such cases can be managed with a thoracoamniotic shunt (TAS). Our objective is to describe postnatal outcomes in survivors after TAS placement for congenital pleural effusions.
A retrospective study of all cases with fetal pleural effusions treated between 2006 and 2016. Patients with dominant unilateral or bilateral pleural effusions complicated by secondary hydrops fetalis received TAS placement. The results are reported as median (range).
A total of 29 patients with pleural effusion with secondary hydrops underwent TAS placement. The gestational age at the initial TAS placement was 27.6 (20.3-36.9) wk. Before delivery, hydrops resolved in 17 (58.6%) patients. The delivery gestational age was 35.7 (25.4-41.0) wk and the overall survival rate was 72.4%. Among the 21 survivors, 19 (90.5%) required admission to the neonatal intensive care unit for 15 (5-64) d. All 21 survivors had postnatal resolution of the pleural effusions. All 21 children were long-term survivors, with a median age of survivorship of 3 y 3 mo (9 mo-7 y 6 mo) at the time of last reported follow-up.
Thoracoamniotic shunting in fetuses with a dominant pleural effusion(s) and secondary hydrops resulted in a 72% survival rate. Nearly all survivors required admission to the neonatal intensive care unit. However, a majority did not have significant long-term morbidity.
先天性胸腔积液的发病率约为每 15000 例妊娠中出现 1 例,较为罕见。发生继发性胎儿水肿是预后不良的指标,此类病例可通过胸羊水分流术(TAS)进行治疗。我们的目的是描述 TAS 治疗先天性胸腔积液后存活患儿的产后结局。
对 2006 年至 2016 年间所有胎儿胸腔积液病例进行回顾性研究。对于存在单侧或双侧胸腔积液且并发继发性胎儿水肿的患者,采用 TAS 治疗。结果以中位数(范围)表示。
共 29 例存在胸腔积液合并继发性胎儿水肿的患者接受 TAS 治疗。初次 TAS 放置时的孕周为 27.6(20.3-36.9)wk。分娩前,17 例(58.6%)患者水肿消退。分娩时的孕周为 35.7(25.4-41.0)wk,总体存活率为 72.4%。在 21 例存活者中,19 例(90.5%)因需要入住新生儿重症监护病房而住院 15(5-64)d。所有 21 例存活者均在产后胸腔积液得到缓解。所有 21 例患儿均为长期存活者,截至最后一次报告随访时的中位生存时间为 3 岁 3 个月(9 个月-7 岁 6 个月)。
对存在大量胸腔积液和继发性胎儿水肿的胎儿行 TAS 治疗可使存活率达到 72%。几乎所有存活者均需入住新生儿重症监护病房,但大多数患儿无明显的长期并发症。